New drug GEn-1124 tested in just 6 men – first look at how body handles it
NCT ID NCT07185113
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a single oral dose of GEn-1124 in 6 healthy adult men. Researchers measured how the drug moves through the body and checked for any side effects. Participants stayed in the clinic for 2 days and received follow-up phone calls. The goal was to gather basic safety and processing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GEn-1124 (oral capsule)
- What could go wrong
- This is a very early, small study in just 6 healthy men. It only looks at how the drug moves through the body and basic safety, not whether it treats any disease. Many early-stage drugs never advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Zealand Clinical Research (NZCR)
Christchurch, 8011, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple vest make breathing easier?
- Chilly workouts may alter what you eat, small study suggests
- New Parkinson's drug MF1 enters first human safety trial
- AI-Powered training cuts hamstring injury risk in pro footballers
- Beta-Alanine boost for cyclists? new study reveals mixed results
- New Egg-Maturing technique could help women with low IVF success